Rev. OFIL 2017, 27;4:341-345
Fecha de recepción: 02/02/2017 – Fecha de aceptación: 29/03/2017
Díaz Rangel M, Lerma Gaude V, Domingo Chiva E, Sánchez Rubio F, Monteagudo Martínez N, Marco del Río J
Servicio de Farmacia Hospitalaria. Gerencia de Atención Integrada de Albacete (España)
Marca Díaz Rangel
Complejo Hospitalario Universitario de Albacete
C/Hermanos Falcó, 37
Correo electrónico: firstname.lastname@example.org
Objectives: To analyze the use, effectiveness and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis.
Methods: Retrospective observational study in a tertiary hospital. The patients treated with pirfenidone between December 2012 and April 2015 were included. Demographic and clinical data were collected.
Results: 11 patients with mild to moderate idiopathic pulmonary fibrosis were included. The most common adverse effects were photosensitivity (45.5%), anorexia (36.4%) and asthenia (36.4%). Treatment was discontinued due to toxicity in two patients. From the available effectiveness data it was observed that the forced vital capacity in some patients increased while in others it decreased. The percentage of patients with a decrease in forced vital capacity not greater than 10% or death was 63.6% at week 24 and 54.5% at week 52.
Conclusions: The use of pirfenidone has been adequate to recommendations unless the diagnosis due to its difficulty, in some cases was determined as possible or probable. The effectiveness of pirfenidone is considered moderate in reducing lung damage and the safety profile and tolerability according to our data is acceptable. Nonetheless, a greater number of patients and a more exhaustive monitoring of them are needed so as to reach more solid conclusions.
Key Words: Pirfenidone, idiopathic pulmonary fibrosis, safety, effectiveness.